Cyprium Therapeutics Copper Histidinate
Cyprium Therapeutics Inc. | Developing new therapeutics for rare pediatric diseases
About Cyprium Therapeutics Copper Histidinate
Cyprium Therapeutics, Inc., established in 2017 by its parent company Fortress Biotech, operates as a biopharmaceutical firm concentrated on creating treatments for rare pediatric diseases, specifically Menkes disease and other copper metabolism disorders. The company's formation is part of Fortress Biotech's broader strategy to acquire and advance high-potential pharmaceutical assets.
The company's lead product candidate is CUTX-101 (Copper Histidinate), a subcutaneous injectable formulation designed to treat Menkes disease. This condition is a rare, X-linked recessive pediatric disorder resulting from mutations in the copper transporter ATP7A gene, which leads to severe neurological symptoms and is often fatal. CUTX-101 aims to address this by providing a bioavailable form of copper directly into the bloodstream, bypassing the impaired oral absorption pathway in patients. Clinical data has shown that early treatment with CUTX-101 can significantly improve overall survival, reducing the risk of death by nearly 80% compared to untreated historical cohorts and extending median survival from 16.1 months to 177.1 months.
In March 2017, Cyprium entered a Cooperative Research and Development Agreement (CRADA) with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a part of the NIH, to advance the clinical development of CUTX-101. The research program is notably led by Dr. Stephen G. Kaler. The U.S. Food and Drug Administration (FDA) has granted CUTX-101 several important designations, including Priority Review, Breakthrough Therapy, Fast Track, Rare Pediatric Disease, and Orphan Drug. The PDUFA target action date for a decision on the New Drug Application (NDA) is set for June 30, 2025. A similar Orphan Drug Designation has been granted by the European Medicines Agency.
Cyprium's business model involves a strategic partnership and asset transfer. In 2023, Cyprium transferred the proprietary rights and FDA documents for CUTX-101 to Sentynl Therapeutics, Inc., a wholly-owned subsidiary of Zydus Lifesciences. Under this agreement, Sentynl assumed full responsibility for the development and commercialization of CUTX-101. Cyprium remains eligible to receive royalties on net sales and up to $129 million in development and sales milestones. Furthermore, Cyprium retains ownership of any Priority Review Voucher (PRV) that may be issued upon NDA approval, which can be sold or transferred.
Source: Dealroom company dataNews
Open roles
Cyprium Therapeutics Copper Histidinate in the Bay Harbor Islands ecosystem
The Cyprium Therapeutics Copper Histidinate office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
National Institute of Neurological Disorders and Stroke
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cyprium Therapeutics Copper Histidinate on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cyprium Therapeutics Copper Histidinate on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

